BACKGROUND: Compound heterozygotes of the haemochromatosis gene (HFE) variants, H63D and C282Y, have raised transferrin saturation compared with that in the wild type. In the cohort of the Oxford Project To Investigate Memory and Ageing (OPTIMA), bicarriers of the HFE C282Y and the transferrin C2 gene variants are at five times greater risk of developing Alzheimer's disease; the addition of HFE H63D may raise the risk still further. OBJECTIVE: To investigate transferrin saturation by HFE and transferrin genotype among people without dementia-that is, controls and those with mild cognitive impairment (MCI)-and also among those with Alzheimer's disease. METHODS: Serum iron status and genotype were examined of 177 patients with Alzheimer's disease, 69 patients with MCI and 197 controls from the OPTIMA cohort. RESULTS: Although each of these variants alone had relatively little effect on iron status, the combination of either HFE C282Y and HFE H63D or of HFE C282Y and transferrin C2 markedly raised transferrin saturation in those without dementia, but had little effect in those with mature Alzheimer's disease. CONCLUSIONS: These combinations may raise the risk for Alzheimer's disease, owing to higher iron loads and therefore oxidative stress in the preclinical phase. If replicated, these findings will have implications for the prevention of Alzheimer's disease.
BACKGROUND: Compound heterozygotes of the haemochromatosis gene (HFE) variants, H63D and C282Y, have raised transferrin saturation compared with that in the wild type. In the cohort of the Oxford Project To Investigate Memory and Ageing (OPTIMA), bicarriers of the HFE C282Y and the transferrin C2 gene variants are at five times greater risk of developing Alzheimer's disease; the addition of HFE H63D may raise the risk still further. OBJECTIVE: To investigate transferrin saturation by HFE and transferrin genotype among people without dementia-that is, controls and those with mild cognitive impairment (MCI)-and also among those with Alzheimer's disease. METHODS: Serum iron status and genotype were examined of 177 patients with Alzheimer's disease, 69 patients with MCI and 197 controls from the OPTIMA cohort. RESULTS: Although each of these variants alone had relatively little effect on iron status, the combination of either HFE C282Y and HFE H63D or of HFE C282Y and transferrin C2 markedly raised transferrin saturation in those without dementia, but had little effect in those with mature Alzheimer's disease. CONCLUSIONS: These combinations may raise the risk for Alzheimer's disease, owing to higher iron loads and therefore oxidative stress in the preclinical phase. If replicated, these findings will have implications for the prevention of Alzheimer's disease.
Authors: C Ramassamy; D Averill; U Beffert; S Bastianetto; L Theroux; S Lussier-Cacan; J S Cohn; Y Christen; J Davignon; R Quirion; J Poirier Journal: Free Radic Biol Med Date: 1999-09 Impact factor: 7.376
Authors: George Perry; Marta A Taddeo; Robert B Petersen; Rudy J Castellani; Peggy L R Harris; Sandra L Siedlak; Adam D Cash; Quan Liu; Akohiko Nunomura; Craig S Atwood; Mark A Smith Journal: Biometals Date: 2003-03 Impact factor: 2.949
Authors: M Kivipelto; E L Helkala; M P Laakso; T Hänninen; M Hallikainen; K Alhainen; H Soininen; J Tuomilehto; A Nissinen Journal: BMJ Date: 2001-06-16
Authors: H A Jackson; K Carter; C Darke; M G Guttridge; D Ravine; R D Hutton; J A Napier; M Worwood Journal: Br J Haematol Date: 2001-08 Impact factor: 6.998
Authors: A Nunomura; G Perry; G Aliev; K Hirai; A Takeda; E K Balraj; P K Jones; H Ghanbari; T Wataya; S Shimohama; S Chiba; C S Atwood; R B Petersen; M A Smith Journal: J Neuropathol Exp Neurol Date: 2001-08 Impact factor: 3.685
Authors: Paolo Zatta; Luigi Messori; Pierluigi Mauri; Susan J van Rensburg; Johann van Zyl; Silvia Gabrielli; Chiara Gabbiani Journal: Biochim Biophys Acta Date: 2005-09-25
Authors: J S K Kauwe; S Bertelsen; K Mayo; C Cruchaga; R Abraham; P Hollingworth; D Harold; M J Owen; J Williams; S Lovestone; J C Morris; A M Goate Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-06-05 Impact factor: 3.568
Authors: Ananya Roy; Adrienne S Ettinger; Howard Hu; David Bellinger; Joel Schwartz; Rama Modali; Robert O Wright; Kavitha Palaniappan; Kalpana Balakrishnan Journal: Neurotoxicology Date: 2013-05-31 Impact factor: 4.294